“We are developing a second generation monoclonal antibody that has already passed the first clinical phase, with excellent results also against all variants of the coronavirus Sars-CoV-2. We are about to face the next two phases but we need candidates and funding. “This was stated by Rino Rappuoli, scientific director and head of Research and Development of GlaxoSmithKline, speaking at the” Researcher’s Day “at Maugeri in Pavia.” Our monoclonal antibody neutralizes all variants of the virus and is administered by injection and no longer intravenously, even at the patient’s home or in a doctor’s office, at a lower price, “he added. (COVID VACCINE: DATA AND GRAPHICS ON ADMINISTRATIONS IN ITALY, REGION BY REGION)
–
Rappuoli: “Test on 800 people with positive swab”
deepening
Covid in Italy and in the world, the latest news today 20 July. LIVE
–
During his speech, Rappuoli then specified that currently it is not yet possible to predict the expected timeframe for completing the last two phases. clinics. “The program foresees that the test will be carried out on 800 people who have had a positive swab: we started in mid-May and so far we have recruited only a hundred – explained Rappuoli -. It is difficult to contact any candidates for privacy reasons. Regione Toscana is spreading the opportunity via the internet: we hope that this information campaign will produce effective results, otherwise we will have to continue our work abroad “. “In Italy you can do good research, also because we can count on researchers of great value. But today there is still a lack of funding to have internationally competitive laboratories. We hope that the necessary investments will be made with funds from the NRP”, he later specified. the scientific director and head of Research and Development of GlaxoSmithKline.
“Maybe a third dose of vaccine will be needed”
As for the campaign of vaccination national anti-Covid, according to Rappuoli, “perhaps a third dose of vaccines will be needed, 6 months or a year after the first two, to strengthen the defenses and limit the circulation of the virus as much as possible”. Still on the subject of anti-Covid vaccines, Rappuoli then praised the “extraordinary result” obtained “thanks to science and new technologies”, namely that of being able to produce vaccines against Covid-19 in just 10 months.
“But now we must be able to face the danger of variants – he added -. Today there are three types of immunity to face the advance of the virus: natural immunity, which offers low protection; immunity produced by vaccines, already more high; hybrid immunity, which is found in infected patients who are cured and then also vaccinated, which is very high “.
– .
